5HT3R antagonist for use in treating aneurysms and cardiovascular risk
US11986464B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 2, 2022 |
| Grant date | May 21, 2024 |
| Priority date | — |
| Expiry date | May 2, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of treating or reducing risk of aneurysm, reducing cardiovascular risk, reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague in a subject involve administering to the subject an effective amount of a 5HT3R antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.